Evotec SE

General information
Evotec SE
Essener Bogen 7
Manfred Eigen Campus
22419 Hamburg, Hamburg
Germany

Contact person: Christian Wojczewski, Chief Executive Officer
Company main phone: +49 (40) 560810
Company main fax:  +49 (40) 56081222
Website:  https://www.evotec.com
Year founded:1993
Source of foundation:Independent foundation
No. of employees: Worldwide:  4766
Corporate description / mission:
Evotec is a life science company with a business model that delivers on the mission to discover and develop highly effective therapeutics and make them available to the patients. The company’s multimodality platform comprises a combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec leverages data-driven R&D autobahn to cures for proprietary projects and within a network of partners. The company's therapeutic areas include neurology, oncology, as well as metabolic and infectious diseases.
State of ownership: Publicly listed on stock exchange
Headquarters: HQ: Yes
IPO (year): 1999
Categorization
Sector:
  • Biotechnology - Therapeutics and Diagnostics
Subsector:
  • Anti-infectives
  • Antibodies
  • Biosimilars
  • Cell therapy
  • Gene therapy
  • Immunotherapy
  • Small molecules
  • Stem cells
Primary therapeutic areas:
  • Cardiovascular / cardiology
  • Congenital malformations, deformations and chromosomal abnormalities / medical genetics
  • Digestive system / gastroenterology
  • Diseases of the blood and blood-forming organs & immune disorders / hematology / immunology
  • Diseases of the eye / ophthalmology
  • Diseases of the nervous system / neurology
  • Endocrine, nutritional and metabolic diseases / endocrinology
  • Genitourinary system / Urology
  • Infectious and parasitic diseases / infectiology / parasitology
  • Neoplasms / cancer / oncology
  • Pregnancy, childbirth and the puerperium / obstetrics
  • Respiratory / pulmonology
  • Skin and subcutaneous tissue / dermatology
  • Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified
Business model:
  • Business incubation
  • In-licensing
  • Manufacturer
  • Out-licensing
  • R&D
  • Research on contract basis
  • Service company
  • Supplier / Distributor
Customer segments:
  • Large biotech & big pharma
  • Small biotech
Distribution:
  • Direct (own sales force)
Summary Products / Services / Technologies
Number of Biotech Products
Pre-clinical:34
Phase I:10
Phase II:3
On the market:2
Description of products:
EVT201
SKYCovione
CT7001, etc
The company's partnered pipeline' comprises drug candidates initially developed by Evotec, then licensed or transferred to partners for further development; candidates initially developed by Evotec's partners, incorporated into joint research projects where Evotec earns milestone payments or royalties; assets in our co-owned pipeline come from Evotec's portfolio of 20 equity companies.

>250 projects: Partnered, unpartnered, equity, BRIDGEs
Technology used:
iPSC platform
Financing details
Fiscal year (end of) 2024
Revenues:USD 834.34M
R&D expenses:USD 53.24M
Cash:USD 320.76M
Total liabilities:USD 1'005.00M
No. of shares:177'552'992
Market cap. / valuation:USD 1'431.54M
Collaborations & Clients
Partnering strategy / collaborations:
Evotec’s co-ownership model represents a collaborative and
integrated approach to drug discovery and development. By partnering with pharmaceutical and biotech companies, Evotec aims to leverage shared expertise, resources, and risks to drive the development of innovative therapies. Evotec seeks to partner these into collaborations in return for upfront payments, ongoing research payments and significant financial upside through milestones and royalties.

Examples:
Pharma: Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Galapagos, Lilly (Eli Lilly and Company), Merck, Novartis, Pfizer, Sanofi, Takeda
Biotech: Alpine Immune Sciences, Kazia Therapeutics
Non-Profit: US Department of Defense
© 2025 Biotechgate by Venture Valuation
X